# Image Eval Diagnostics: iter3_flow_node_only_sonnet46

## Bucket Counts

- missed node: 9
- extra hallucinated node: 9
- wrong branch direction/label: 9
- variable extraction miss: 9
- ambiguity unresolved: 9

## Per-Case Bucket Distribution

### diabetes_treatment
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

### liver_pathology
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

### workflow_test
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

## Trial Notes

### workflow_test trial 1 - composite 33.44
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has two separate 'Are They Optimised on treatment?' nodes: one for the primary/on-therapy path and one for the specialist/secondary path at the top. The top path (Under Specialist Clinic? -> No -> total cholesterol > 7.5 -> optimised on treatment?) leads to either 'Consider Lipid Clinic Referral' / 'Refer to specialist' or 'Send Lipid Lowering Therapy AccuRx'. This secondary path was not fully captured due to tree constraints (single-root, no merging nodes).; The diagram shows a threshold of > 7.5 and <= 7.5 for total cholesterol when under specialist clinic is No, but the routing after this is complex and involves re-entry into the 'Under Specialist Clinic?' node or a separate path. It is unclear if > 7.5 leads directly to the specialist optimised-on-treatment check or if there is an intermediate step.; The 'not coded, assume no' yellow sticky note next to 'Under Specialist Clinic?' suggests a default assumption but is not a formal flow node.; The 'Primary/Secondary Treatment' label appears twice as annotation boxes pointing into different flow nodes, making it ambiguous whether they represent separate inputs or the same concept.; The 'Consultation' yellow box near the top right appears next to 'Send Lipid Lowering Therapy AccuRx' but it is unclear if it is a flow node or an annotation.

### workflow_test trial 2 - composite 43.18
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The 'not coded, assume no' annotation near the Under Specialist Clinic decision implies a default value; this is treated as edge_label false (not under specialist clinic) but may vary by implementation.; The 'We assume Normal to be 5 or below (can vary from clinic to clinic)' annotation is a guidance note, not a flow node; the threshold for Normal vs Raised may differ per clinic.; The 'Primary/Secondary Treatment' label appears on a yellow sticky note near the upper branch (optimised on treatment = No), suggesting further branching, but arrows are ambiguous. The flow to 'Refer to specialist' vs 'Send Lipid Lowering Therapy' is inferred from diagram context.; The 'Consultation' label near the upper 'Are They Optimised on treatment?' node appears to be an annotation, not a distinct flow step.; The LDL 2-2.5 branch has a complex sub-flow involving Inclisiran and Ezetimibe; the exact branching logic between 'Has had 6 months of Inclisiran' and LDL >2.0 check may not be fully captured.

### workflow_test trial 3 - composite 39.32
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The 'Under Specialist Clinic?' node has 'not coded, assume no' annotation suggesting default value; it's unclear if this is always assumed false or is a real input.; The 'Normal or Raised?' decision connects back with two separate paths (>7.5 branch goes to Under Specialist Clinic, ≤7.5 goes to Normal or Raised?), but the diagram shows Assess Total Cholesterol feeding into both thresholds - the exact routing logic around >7.5 vs ≤7.5 and then Normal/Raised is ambiguous.; The 'Consider Lipid Clinic Referral' and 'Refer to specilaist' nodes in the top optimised-on-treatment branch appear as two separate outputs from the same 'yes' branch - it's unclear if they are sequential or parallel or alternative outcomes.; The 'Primary/Secondary Treatment' action node in the lower 'Are They Optimised on treatment? - Yes' branch leads nowhere explicitly in the diagram; it seems to loop or terminate - its children are unclear.; The sticky note 'We assume Normal to be 5 or below (can vary from clinic to clinic)' is an annotation influencing the Normal/Raised threshold but is not a flow node.

### diabetes_treatment trial 1 - composite 26.28
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The 'Not tolerated** switch to' arrow from Metformin (CVD path) leading to a different branch is ambiguous - it is unclear where exactly 'not tolerated' redirects in the CVD path (possibly to SGLT2i directly or to a different drug).; The 'Minimum BMI for GLP Initiation is 23' box appears to be an annotation/condition for starting GLP/Ozempic but has no clear flow arrow - treated as annotation not a flow node.; The 'High prognostic value' and 'Low prognostic value' nodes are shown as decision/branch points but the diagram uses them as labels on branches from a single decision - interpretation as a single decision node is assumed.; It is unclear whether the 'Add GLP' and subsequent Ozempic/Mounjaro path is only triggered from triple therapy or also from other paths; the diagram suggests it follows triple therapy.; The 'Despite Optimisation and maximally tolerated dose A1C >58' node on the right side appears to connect back to 'Refer to Insulin Initiator' but also connects from the Ozempic (CVD path) - the exact flow merge is ambiguous.

### diabetes_treatment trial 2 - composite 31.37
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The 'Not tolerated** switch to' branch from Metformin in the CVD pathway is shown but does not have a clearly labeled destination node distinct from the main flow - it appears to loop back or switch to a different add-on; this path is not captured as a separate branch.; The 'Minimum BMI for GLP Initiation is 23' annotation appears near the CVD/SGLT2i pathway but is not clearly a flow node; it may be a prerequisite condition for Ozempic initiation that is not modeled.; The 'Add GLP' node in the triple therapy pathway seems to feed into both 'High prognostic value' and 'Low prognostic value' branches simultaneously, but the diagram also shows Ozempic/Mounjaro as direct outputs from those branches - the exact flow structure is slightly ambiguous.; The dual therapy branch ('Gliptin Or Pioglitazone Or Gliclazide') is modeled as a terminal output, but the diagram implies that if A1c remains uncontrolled after dual therapy, the flow continues to triple therapy. The merge/continuation point is ambiguous.; The 'Metformin AccuRx' box in the top right appears to be a reference/informational panel and not a flow node; it is excluded.

### diabetes_treatment trial 3 - composite 24.8
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram shows two separate Metformin starting points: one for 'CVD Known or Risk' patients and one for 'Not at risk of CVD' patients. The tree structure forces a single root, so the CVD branch and non-CVD branch have been merged under the CVD decision node.; The 'Not tolerated** switch to' arrow from Metformin (CVD path) pointing back toward the non-CVD dual therapy path is ambiguous - it's unclear if intolerant CVD patients should follow the non-CVD algorithm or a separate path.; The 'Minimum BMI for GLP Initiation is 23' annotation appears near the SGLT2i/Ozempic pathway but has no explicit flow arrows - treated as informational note only.; The connection between the Ozempic node in the CVD pathway and the 'Refer to Insulin Initiator' node is mediated by 'A1c not controlled' but the diagram also shows 'Despite Optimisation and maximally tolerated dose A1C >58' as a separate node - it is unclear if these are the same condition or sequential steps.; The triple therapy branch also has an 'Add GLP' step before the High/Low prognostic value split - it is unclear if GLP is added for all triple therapy patients or only some.

### liver_pathology trial 1 - composite 13.87
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram shows multiple feedback loops (e.g., Review Result feeding back into Telephone Consultation, and Phase 4 Bloods appearing multiple times). These cycles cannot be perfectly represented in a strict tree structure; some nodes have been duplicated to approximate the flow.; The 'Need to rationalise which Additional tests should be done for rare conditions' box role in the flow is ambiguous - it appears as an annotation/guidance rather than a clear executable node.; FIB4 score thresholds shown in diagram (<1.3 or <2.0 if age>65 for Low Risk; >1.3 and >2.67 for High Risk) and NAFLD score thresholds (-1.455 to 0.675 for Indeterminate, <-1.455 for F0-F2, >0.675 for F3-F4) are visible but the exact branching logic based on age >65 makes the FIB4 decision more complex than a simple binary split.; The 'Review Result' node appears multiple times in the diagram collecting results from multiple test branches before feeding into Telephone Consultation; the exact merge logic is unclear.; Phase 4 Bloods appears as both a starting point for conditional/mandatory testing and as a downstream node after F3-F4 determination - the intended flow is ambiguous.

### liver_pathology trial 2 - composite 17.13
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has multiple arrows converging back to 'Phase 4 Bloods' and 'Review Result'/'Telephone Consultation' nodes, making it a graph rather than a strict tree. The JSON tree representation required forced some convergence points to be duplicated as separate leaf/subtree nodes.; The FIB-4 Categories thresholds differ by age (>=65 uses different cutoffs: 1.3 vs 2.0 for low, 2.67 for high risk). The exact age-adjusted logic is partially captured but may not be fully precise.; The 'Review Result' node appears to be shared between Mandatory Testing and Conditional Testing branches, but the tree structure requires duplication.; The 'Phase 4 Bloods' node appears multiple times in the diagram (convergence from NAFLD/FIB-4 paths and from the F3-F4 path). These have been represented as separate nodes in the tree.; The 'Telephone Consultation' node receives inputs from multiple paths (mandatory testing review, conditional testing review, and potentially the 'normal' result path). The tree forces these to be modeled as separate nodes.

### liver_pathology trial 3 - composite 18.12
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has multiple 'Phase 4 Bloods' boxes and 'Refer to Secondary Care' boxes that appear to be reused nodes in a flowchart; they have been modeled as separate leaf/action nodes in the tree since a true tree cannot have shared nodes.; The 'Review Result' node receives arrows from multiple conditional testing branches (Haemachromatosis Gene Test, Primary Biliary Cirrhosis Screen, Autoimmune Hepatitis screens, Wilsons Screen) - this convergence cannot be fully represented in a strict tree; only the primary path through the mandatory/conditional testing is modeled.; The FIB-4 Categories thresholds differ by age (1.3 or <2.0 if age >=65; 2.67 at any age or >=2.0 if age >=65) - the exact age-adjusted logic is complex and only partially captured.; The NAFLD Fibrosis Score categories use age-adjusted thresholds (<-1.455, -1.455 to 0.675, >0.675) which are simplified here.; The 'Code as normal USS and file' node appears to apply when findings are present for <3 months and result is normal, but its exact trigger in context of the full flow is ambiguous.
